IMEXHS LIMITED — Investor Presentation 2021

Mar 17, 2021

==> picture [149 x 353] intentionally omitted <==

==> picture [45 x 86] intentionally omitted <==

Built by physicians for physicians

Coffee MicroCaps

18 March 2021

==> picture [259 x 286] intentionally omitted <==

==> picture [146 x 61] intentionally omitted <==

Innovative provider of cloud-based medical imaging software solutions

IMEXHS LTD | (ASX:IME)

2

Built by physicians for physicians

==> picture [146 x 61] intentionally omitted <==

2012 2016 2018 2020 Founded in Colombia Release zero IMEXHS lists Launched Aquila in by two Professors of footprint WEB on ASX the Cloud, open US office, certification Neuroradiology & viewer in Brazil and EU, radiology software new partners engineer 2015 2017 2019 Expand Implement solutions Receive FDA Clearance in outside across 200 USA, new medical verticals Colombia healthcare sites & AI tools, new markets

IMEXHS LTD | (ASX:IME)

3

Expanding global footprint

Spain USA Mexico Honduras El Salvador Nicaragua Australia Costa Rica Colombia Panama Ecuador Peru Brazil Bolivia Paraguay Chile Uruguay IMEXHS currently operating Argentina Agreement being negotiated

==> picture [146 x 61] intentionally omitted <==

15 countries >250 sites >2,100 radiologists 23 distributors 1/3 of team in software development

4

IMEXHS LTD | (ASX:IME)

Leading innovator in medical imaging

==> picture [146 x 61] intentionally omitted <==

• Multi-tenant architecture, cloudbased medical imaging software

• HIRUKO[TM] platform provides solutions for all complexity levels

• Subscription model with high recurring revenue from multi-year contracts

• Aquila in the Cloud standardised radiology solution

• Multiple distribution channels across 15 countries

• Developing AI tools - large proprietary database of 940m stored images

IMEXHS LTD | (ASX:IME)

5

Multiple runways for growth

==> picture [146 x 61] intentionally omitted <==

Aquila Custom

• Aquila customised radiology offering

• 5-year contracts on average

• Subscription model

Aquila in the Cloud

Other Medical Verticals

• Alula – pathology

• • Anteros – cardiology

• Standardised radiology solution • Anteros – cardiology

• • 1-2 year contracts on • Extend into other

• average verticals

• Volume-based model

Expanding into new geographies including US and Brazil

IMEXHS LTD | (ASX:IME)

6

HIRUKO[TM] medical imaging platform

==> picture [146 x 61] intentionally omitted <==

==> picture [650 x 276] intentionally omitted <==

----- Start of picture text -----

Advanced Stella Vital Alma
Braviz
Post-processing AI 3D ADv 3D Basic
Enterprise Aquila Alula Anteros
Imaging Radiology Pathology Cardiology
HIRUKO [TM] Universal
Core Platform Portals Multi-Tenancy
PACS/VNA Viewer
Nuance 360
----- End of picture text -----

IMEXHS LTD | (ASX:IME)

7

*Components in blue represent IMEXHS proprietary technology

==> picture [720 x 138] intentionally omitted <==

----- Start of picture text -----

End-to-end modular imaging solution
----- End of picture text -----

==> picture [707 x 240] intentionally omitted <==

----- Start of picture text -----

Scan scheduled Uploaded Archived on our 1)Business
Manages
via our to our platform cloud-based Intelligence
Billing
platform platform } 2)Statistical
Data
3. 4. 5.
1. 2. Radiologist Referring Physician Billing
Physician Patient has interprets scanned reviews images via (where
requests patient scheduled scan images Referring applicable)
scan ( Tele-Radiology [1] ) Physician Portal
1 Teleradiology - radiology concerned with the transmission of digitised medical images (as X-rays, CT scans, and sonograms) over electronic networks and with the interpretation of the
transmitted images for diagnostic purposes
----- End of picture text -----

IMEXHS LTD | (ASX:IME)

8

Aquila in the Cloud

• Aquila in the Cloud, standardised radiology solution, launched in May 2020

• Provides small and medium-sized customers with low-cost, rapidly deployed product offering

• At 31 Dec 2020, 41 deals signed, estimated ARR contribution of $945k. This increased to 48 deals at 24 February 2021.

• At 16 March 2021, 54 deals signed with ARR contribution of $1.2m.

• Distribution via growing partner network and online marketplaces

• Strong pipeline of new opportunities

==> picture [146 x 61] intentionally omitted <==

==> picture [287 x 252] intentionally omitted <==

----- Start of picture text -----

$1,200k
54
$945k
41
$675k
$473k 28
$400k
17
12
Sept Oct Nov Dec Mar
New contracts (cumulative) ARR contribution
----- End of picture text -----

IMEXHS LTD | (ASX:IME)

9

Range of solutions for AiC customers

==> picture [146 x 61] intentionally omitted <==

==> picture [578 x 276] intentionally omitted <==

----- Start of picture text -----

LITE PRO ULTIMATE
Multiplatform
Unlimited Users
Unlimited Exams
100% Web Platform Modality Worklist Management Scheduling
VNA | PACS Archiving Digital Signature in Reports SMS notifications
Web Viewer VR Web (Reporting) () Patient Admission
Results Distribution Results Distribution Questionnaire
Standard KPIs Patient & Physician Portal Business Intelligence (BI)
----- End of picture text -----*

IMEXHS LTD | (ASX:IME)

10

Multiple distribution channels

==> picture [146 x 61] intentionally omitted <==

• Distributors partners represent important sales channel for both Aquila Custom and Aquila in the Cloud

• Established new distribution channel in April 2020 with acceptance on Ingram’s Micro Cloud marketplace

==> picture [533 x 189] intentionally omitted <==

----- Start of picture text -----

DISTRIBUTION CHANNELS
DIRECT SALES DISTRIBUTORS
• Mainly in Colombia, US • Agreements with distributor partners
• Global cloud marketplace • Low risk go-to-market strategy
Private Hospitals & Clinics Public Hospitals & Clinics Private Practices
----- End of picture text -----

IMEXHS LTD | (ASX:IME)

11

Developing AI capabilities

==> picture [146 x 61] intentionally omitted <==

• Images almost doubled to 940m reflecting full year of Colsubsidio contract Number of Images Stored (m)

==> picture [632 x 162] intentionally omitted <==

----- Start of picture text -----

940
•
Important test bed for the development and
training of AI tools
• Developed Stella AI which identifies normal and 488
pathological radiological patterns in chest x-
rays 231
99
• 32
Released non-imaging AI tools in natural
language processing
2016 2017 2018 2019 2020
----- End of picture text -----

IMEXHS LTD | (ASX:IME)

12

FY20 Financial Highlights

==> picture [146 x 61] intentionally omitted <==

Sales Revenue of ARR of EBITDA of $10.9m $10.1m ($1.3m) Up 41% yoy[1] , new contract Up 19% yoy, 33% higher on a Improvement of $3.3m, wins & renewals constant currency basis $2.5m on like for like basis[3] Underlying EBITDA[4] of Recurring revenue of Closing cash of $8.5m ($0.7m) $10.8m Improvement of $3.8m, Up 29% yoy[2] $7.1m at 31 Dec 2019 $3.0m on a like for like basis[3]

1. Sales revenue up 59% on a constant currency basis 2. Recurring revenue up 45% on a constant currency basis

2. Adjusting for the impact of software capitalisation policy adopted in FY20 4. Refer Slide 20 of FY20 Investor Presentation for Underlying EBITDA reconciliation 5. FY20 results are preliminary / unaudited

IMEXHS LTD | (ASX:IME)

13

Strong growth in ARR

==> picture [325 x 206] intentionally omitted <==

----- Start of picture text -----

20162017201820192020 Annualised Recurring Revenue
12
10
8
6
4
2
0
2016 2017 2018 2019 2020
Spot Not Yet Billing Constant Currency Not Yet Billing
$ m
----- End of picture text -----

==> picture [146 x 61] intentionally omitted <==

• Annual Recurring Revenue (ARR) of $10.1m, up 19% yoy (33% on constant currency basis)

• Recent contract wins include Gables Radiology in the US, Keralty (Colombia), and Laboratorios Santa Maria (Mexico)

• Contract renewals and extensions include National Police Hospital in Bogotá (Colombia) and Corominas y Castillo (Mexico)

IMEXHS LTD | (ASX:IME)

14

Increasing use of Large, rapidly radiological Chronic global Shift from client growing but highly Increased proportion techniques in wider radiologist shortage server architecture to fragmented global of the value chain clinical applications, driving demand for fully web-based cloud medical imaging coming from AI demand for central teleradiology solutions sector storage of images STRATEGIC PRIORITIES: Benefiting from industry tailwinds ‘Land & expand’ Geographic Teleradiology Large AI image library strategy with multiple Aquila in the Cloud expansion across solution allows and radiology verticals including low touch multiple markets, radiologists to access services drive cardiology and deployment model leverage specialist images from any development of AI pathology, VNA for small clinics distributors device or location tools capability

STRATEGIC PRIORITIES: Benefiting from industry tailwinds

IMEXHS LTD | (ASX:IME)

15

2021 Product Roadmap

==> picture [62 x 62] intentionally omitted <==

==> picture [62 x 62] intentionally omitted <==

AQUILA 4.0 with new features and functions orientated to US and Australian markets

• Alula Marketplace , the world’s first dedicated pathology marketplace workflow program

Democratising access to high-tech medical imaging platforms

==> picture [62 x 62] intentionally omitted <==

Other medical verticals

• Dental Imaging platform

• Veterinary Information System

==> picture [146 x 61] intentionally omitted <==

==> picture [62 x 62] intentionally omitted <==

AI Algorithms

• Automatic detection and segmentation of lung areas with consolidation and ground glass opacities on CT scans

• Automatic selection from a radiologist worklist and posterior rendering of functional MRI and DTI tractography

IMEXHS LTD | FY20 FINANCIAL RESULTS (ASX:IME)

16

FY21 Outlook

Aquila in the Cloud (AiC) – Leverage distribution partners to convert strong interest across all markets

US – build presence with AiC offering and via online marketplaces

New markets – open office in Brazil and explore opportunities in EU

==> picture [146 x 61] intentionally omitted <==

2021 trading to date in line with Company expectations

Improved outlook for key markets despite second waves of COVID-19 On track to achieve monthly run rate EBITDA breakeven by December 2021

IMEXHS LTD | (ASX:IME)

17

==> picture [135 x 48] intentionally omitted <==

==> picture [36 x 109] intentionally omitted <==

WWW.IMEXHS.COM

18

Disclaimer

==> picture [146 x 61] intentionally omitted <==

The information contained in this Presentation or subsequently provided to the Recipient of this Presentation, whether orally or in writing by or on behalf of ImExHS Limited or its respective employees, agents or consultants (“Information”) is provided to the Recipient on the terms and conditions set out in this notice.

The Recipient should not treat the Information as advice relating to legal, taxation, financial product or investment matters and should consult their own advisers. This Presentation does not purport to contain all the information that a prospective investor may require. The Information may not be appropriate for all persons and it is not possible for ImExHS Limited to have regard to the investment objectives, financial situation and particular needs of each Recipient who reads or uses the Information . Accordingly, no recommendation or expression of opinion is contained within the Information. Further, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the Information, including the likelihood of achievement or reasonableness or any forecasts, prospects or returns contained in the Information. Before acting in reliance on any Information, the Recipient should conduct their own investigation and analysis in relation to the investment opportunity presented by this Presentation and should check the accuracy, reliability and completeness of the Information and obtain independent and specific advice from appropriate professional advisers.

Statements contained in the Information, particularly those regarding possible or assumed future performance or potential growth, prospects or projections of ImExHS Limited are, or may be, forward looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks, uncertainties and contingencies. The Information may also be subject to clarification and change and ImExHS Limited may in its absolute discretion, but without being under any obligation to do so, update, amend or supplement the Information. The Information is for informational purposes only and does not constitute an offer to issue, or arrange to issue, securities or other financial products. The Information is not, and should not be construed to be, a Prospectus.

To the maximum extent permitted by law none of ImExHS Limited or its respective employees, agents or consultants nor any other person accepts any liability, including, without limitation, any liability arising out of fault of negligence, for any loss arising from the use of the Information.

19